Is there another chapter in the Helicobacter pylori/peptic ulcer disease story?
Related Experiment Video
Updated: Oct 5, 2026

Profiling Luminal pH in Three-Dimensional Gastrointestinal Organoids Using Microelectrodes
Published on: July 5, 2024
1Discipline of Immunology and Microbiology, University of Newcastle and Vasse Research Institute, New South Wales, Australia. rclancy@mail.newcastle.edu.au
Abstract:
The role of Helicobacter pylori in the production of mucosal damage has largely been considered within a simple infection paradigm, because to date eradication has appeared to be a predictable outcome of antibiotic therapy. Changes in the epidemiology and management of peptic ulcer disease, however, require a more comprehensive framework to understand these shifting clinical patterns. The present review examines mucosal damage as an outcome of a complicated host-parasite relationship, with alterations in both parasite physiology and host defence mechanisms being keys to understanding disease patterns.
Related Concept Videos
Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer
Gastritis II: Pathophysiology
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
